Phase 2 Study of SK-1011 - Subfoveal choroidal neovascularization secondary to age-related macular degeneration
Phase 2
- Conditions
- Subfoveal choroidal neovascularization secondary to age-related macular degeneration
- Registration Number
- JPRN-jRCT2080221648
- Lead Sponsor
- SANWA KAGAKU KENKYUSHO CO.,LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1) Age-related macular degeneration patients diagnosed with subfoveal choroidal neovascularization in the study eye
2) Patients who have a BCVA ETDRS score between 73 and 24 letters in the study eye inclusive (approximately 0.5 to 0.06)
3) Patients who are capable of giving written informed consent
Exclusion Criteria
1) Use of systemic anti-VEGF medication
2) Prior treatment in the study eye with anti-VEGFs, verteporfin, steroids, or laser photocoagulation within certain periods of time
3) Presence of retinal angiomatous proliferation (RAP) in the study eye
4) Medical conditions such as cancer, serious liver, renal cardiac disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy and safety
- Secondary Outcome Measures
Name Time Method